Eplerenone in the Central Serous Chorioretinopathy Chronic
International Journal of Ophthalmology & Visual Science
Volume 5, Issue 2, June 2020, Pages: 66-69
Received: May 21, 2020; Accepted: Jun. 2, 2020; Published: Jun. 17, 2020
Views 188      Downloads 70
Authors
Mehdi Khamaily, Department of Ophthalmology of the Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
Joumany Brahim Salem, Department of Ophthalmology of the Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
Imane Tarib, Department of Ophthalmology of the Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
Wafaa Akioud, Department of Ophthalmology of the Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
Soukaina Haddougui, Department of Ophthalmology of the Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
Yassine Mouzari, Department of Ophthalmology of the Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
Fouad El Asri, Department of Ophthalmology of the Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
Karim Reda, Department of Ophthalmology of the Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
Abdelbarre Oubaaz, Department of Ophthalmology of the Mohammed V Military Teaching Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
Article Tools
Follow on us
Abstract
Summary: Central serous chorioretinitis is a relatively common eye condition. It is a maculopathy of the young subject, characterized by the presence of a retinal serous detachment, usually located at the posterior pole, associated with changes in the pigment epithelium. Materials and methods: a prospective study was conducted between Mars 2018 and Mars 2020 at the Mohammed V military hospital in Rabat, in 11 patients treated with eplerenone for a chronic CRSC evolving for at least 3 months with repercussions on visual acuity, at the dose of 25 mg per day the first week, then 50 mg per day for an average treatment duration of 15 weeks. For each patient, visual acuity and macular OCT (central thickness of the retina) were evaluated before treatment and at 1, 3 and 6 months. Results: The mean age of the patients was 32,54 ± 6,78. 11 men. All patients were under stress, and just two patient reported the notion of taking corticosteroids. The average duration of progression of the pathology before treatment was 20 weeks. A clear improvement in visual acuity (logMAR) was observed in 9 patients: mean visual acuity increased from 0,7 at admission to 0,69 at 1 month (p: 0.014), 0,4 at 3 months (p: 0.013) and 0,28 at 6 months (p: 0.025). The mean central macular thickness decreased from 423 ± 91 μm before treatment, 317 ± 82 μm at 1 month and 292 ± 73,6 μm at 3 months and 251± 94 μm at 6 months (p 0.026, 0.01 and 0.038 respectively). 5 patients had a complete disappearance of SRF at 3 months. 1 other patients had a complete disappearance of the DSR at 6 months. The treatment was stopped for 3 patients, including 1 at 4 weeks for severe muscle cramps, and hyperkaliema for the 2 others at 10 weeks ans 11 weeks of treatment. Conclusion: In our study, the introduction of eplerenone resulted in significant improvement in both anatomical and functional outcomes in patients with chronic CSCR.
Keywords
Chronic Central Serous Chorioretinitis, Eplerenone, Sub-retinal Fluid, Mineralocorticoid Receptor
To cite this article
Mehdi Khamaily, Joumany Brahim Salem, Imane Tarib, Wafaa Akioud, Soukaina Haddougui, Yassine Mouzari, Fouad El Asri, Karim Reda, Abdelbarre Oubaaz, Eplerenone in the Central Serous Chorioretinopathy Chronic, International Journal of Ophthalmology & Visual Science. Vol. 5, No. 2, 2020, pp. 66-69. doi: 10.11648/j.ijovs.20200502.16
Copyright
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Summary: Central serous chorioretinitis is a relatively common eye condition. It is a maculopathy of the young subject, characterized by the presence of a retinal serous detachment, usually located at the posterior pole, associated with changes in the pigment epithelium. Materials and methods: a prospective study was conducted between Mars 2018 and Mars 2020 at the Mohammed V military hospital in Rabat, in 11 patients treated with eplerenone for a chronic CRSC evolving for at least 3 months with repercussions on visual acuity, at the dose of 25 mg per day the first week, then 50 mg per day for an average treatment duration of 15 weeks. For each patient, visual acuity and macular OCT (central thickness of the retina) were evaluated before treatment and at 1, 3 and 6 months. Results: The mean age of the patients was 32,54 ± 6,78. 11 men. All patients were under stress, and just two patient reported the notion of taking corticosteroids. The average duration of progression of the pathology before treatment was 20 weeks. A clear improvement in visual acuity (logMAR) was observed in 9 patients: mean visual acuity increased from 0,7 at admission to 0,69 at 1 month (p: 0.014), 0,4 at 3 months (p: 0.013) and 0,28 at 6 months (p: 0.025). The mean central macular thickness decreased from 423 ± 91 μm before treatment, 317 ± 82 μm at 1 month and 292 ± 73,6 μm at 3 months and 251± 94 μm at 6 months (p 0.026, 0.01 and 0.038 respectively). 5 patients had a complete disappearance of SRF at 3 months. 1 other patients had a complete disappearance of the DSR at 6 months. The treatment was stopped for 3 patients, including 1 at 4 weeks for severe muscle cramps, and hyperkaliema for the 2 others at 10 weeks ans 11 weeks of treatment. Conclusion: In our study, the introduction of eplerenone resulted in significant improvement in both anatomical and functional outcomes in patients with chronic CSCR.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186